<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<pubmed-document>
<record>
<header>
<identifier>27912913</identifier>
<setSpec>1989-7286</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:author>Cuesta-Lasso, M</dc:author>
<dc:author>Amselem, L</dc:author>
<dc:author>Badal, J</dc:author>
<dc:author>Vieira-Barros, A</dc:author>
<dc:author>Dolz-Marco, R</dc:author>
<dc:author>Díaz-Llopis, M</dc:author>
<dc:author>Roig-Revert, M J</dc:author>
<dc:author>Gallego-Pinazo, R</dc:author>
<dc:description xml:lang="en">OBJECTIVE To evaluate the efficacy of intravitreal therapies in cases of atrophic age-related macular degeneration (AMD) with subretinal or intraretinal fluid. METHODS A retrospective review was made of the clinical charts of patients diagnosed with atrophic AMD with subretinal or intraretinal fluid. Fundus photographs and spectral-domain optical coherence tomography images were examined, and an analysis was made on the presence of fluid and its density. Neovascularisation was ruled out by fluorescein and/or indocyanine green angiography. RESULTS The study included 14 eyes from 13 patients with a mean age of 72.64 years and a mean follow-up of 80.5 weeks. Intraretinal fluid was observed in 6 eyes (42.9%), while subretinal fluid was shown in 8 eyes (57.1%), with high density in 4 eyes (28.5%), and low density in 4 eyes (28.5%). Snellen best-corrected visual acuity improved from 0.37 at baseline to 0.56 at the final visit (P=.002). Central subfield thickness (microns) significantly decreased (P&lt;.001) from 291.0 at baseline to 228.9 at the final visit. Eight eyes received ranibizumab, 5eyes received bevacizumab, and one case received triamcinolone. CONCLUSIONS Cases of atrophic AMD may present with subretinal or intraretinal fluid in the absence Neovascularisation. Further studies are required to analyse the value of this finding as a risk factor of developing advanced forms of AMD, as well as the efficacy of intravitreal therapies.</dc:description>
<dc:type>Journal Article</dc:type>
<dc:language>es</dc:language>
<dc:subject>Spectral domain optical coherence tomography</dc:subject>
<dc:subject>Fluido intrarretiniano</dc:subject>
<dc:subject>Fluido subretiniano</dc:subject>
<dc:subject>Degeneración macular asociada a la edad no neovascular</dc:subject>
<dc:subject>Subretinal fluid</dc:subject>
<dc:subject>Terapias intravítreas</dc:subject>
<dc:subject>Tomografía de coherencia óptica de dominio espectral</dc:subject>
<dc:subject>Non-neovascular age related macular degeneration</dc:subject>
<dc:subject>Intraretinal fluid</dc:subject>
<dc:subject>Intravitreal therapies</dc:subject>
<dc:date>2017 Mar </dc:date>
<dc:title xml:lang="es">Terapias intravítreas en degeneración macular asociada a la edad no neovascular con fluido intrarretiniano o subretiniano.</dc:title>
<dc:title xml:lang="en">Intravitreal therapies for non-neovascular age-related macular degeneration with intraretinal or subretinal fluid.</dc:title>
<dc:publisher>Archivos de la Sociedad Espanola de Oftalmologia</dc:publisher>
</metadata>
</record>
</pubmed-document>
